| Customization: | Available |
|---|---|
| Powder: | Yes |
| Customized: | Customized |
|
Still deciding? Get samples of $ !
Request Sample
|
Suppliers with verified business licenses
Audited Supplier Audited by an independent third-party inspection agency
Tideglusib (NP-12, NP031112) is a potent, selective and irreversible small molecule non-ATP-competitive glycogen synthase kinase 3 (GSK-3) inhibitor.. Other GSK inhibitors. There are few classes of GSK-inhibitors, including lithium (Martinez et al., 2011), the small peptide L803mts10, and members of the thiazolidinedione family, containing non-competitive inhibitors of GSK-3, such as TDZD-8.Tideglusib is a GSK-3 inhibitor currently in phase II clinical trials for the treatment of Alzheimer disease and progressive supranuclear palsy.
| Product name | Tideglusib |
| Appearance | white Powder |
| Specification | 98% |
| Shelf life | 2 years when properly stored |
Tideglusib was originally developed to treat Alzheimer's disease, but it was unexpectedly discovered that it can be used to regenerate damaged teeth. Tideglusib is an irreversible, non-ATP-competitive GSK-3β inhibitor with IC50 of 60 nM.On November 9, 2020, AMO pharma announced that the FDA has granted its investigational therapy AMO-02 (tideglusib) Rare Pediatric Disease (RPD) designation for the treatment of congenital myotonic dystrophy.
){kind=link}